Figure 3
From: Activation of AMPK inhibits cervical cancer cell growth through AKT/FOXO3a/FOXM1 signaling cascade
Activation of AMPK represses FOXM1 expression through inhibiting the AKT/FOXO3a signaling pathway. (A) Upon treatment of metformin (25 mM) in cervical cancer cells (C33A), the expression of FOXM1 diminished remarkably and the phosphorylation of AKT and AKT-specific phosphorylation of FOXO3a (Ser253) decreased concomitantly. (B) Co-treatment of PI3K/AKT inhibitor, LY294002 (10 μM), inhibited p-AKT and concomitantly reduced the levels of FOXO3a (Ser253) and FOXM1 in C33A cells. (C) Depletion of endogenous FOXO3a in C33A cells using siRNAs showed that FOXO3a expression is required for the suppression of FOXM1 by metformin (25 mM) treatment.